IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten
NCT07716826
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Cardiomyopathy, Hypertrophic Obstructive
Sponsor
French Cardiology Society